<DOC>
	<DOCNO>NCT00818441</DOCNO>
	<brief_summary>This study explore safety efficacy oral PanHER inhibitor PF-00299804 patient adenocarcinoma lung either non-smokers ( &lt; 100 cigarette , cigar pipe lifetime ) former light smoker ( less 10 pack-years stop least 15 year ) know EGFR activate mutation ; patient HER 2 amplification mutation .</brief_summary>
	<brief_title>Dacomitinib ( PF-00299804 ) As A Single Oral Agent In Selected Patients With Adenocarcinoma Of The Lung</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<criteria>Advanced adenocarcinoma lung , measurable disease Nonsmoker , former light ( le 10 pack year stop least 15 year ) ; OR patient know EGFR activate mutation regardless smoke status ECOG ( Eastern Cooperative Oncology Group ) 01 . Cohort B ( select site ) : patient HER2 amplify HER2 mutationpositive NSCLC ; may prior therapy Active brain metastasis Prior systemic therapy advance disease Cohort A . Cohort B number prior line systemic therapy . know EGFR wild type NSCLC</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>lung cancer adenocarcinoma HER2</keyword>
</DOC>